Data / Drug companies / Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc.: 23 products in the FDA NDC directory, labeler code 50111
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Teva Pharmaceuticals USA, Inc. (labeler code 50111) lists 23 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 19 prescription drugs, 4 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 20, 2025.
The request: Watch Teva Pharmaceuticals USA, Inc. (FDA labeler code 50111): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50111
- Products in commercial distribution
- 23
- Packages
- 46
- Finished drugs by generic name
- 7
- Prescription products
- 19
- Over the counter products
- 0
- Flagged as original packager
- 16 of 16 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 82.6% |
| Drugs for further processing | 4 | 17.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 19 | 82.6% |
| Drugs for further processing | 4 | 17.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Torsemide | 4 | 25 |
| Hydralazine hydrochloride | 4 | 47 |
| Trazodone hydrochloride | 3 | 39 |
| Azithromycin | 3 | 41 |
| Metronidazole | 2 | 68 |
| Fluoxetine | 2 | 42 |
| Oxybutynin chloride | 1 | 45 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 18 | 78.3% |
| Tablet, film coated | 3 | 13% |
| Capsule | 2 | 8.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Serotonin Reuptake Inhibitor | 5 |
| Loop Diuretic | 4 |
| Arteriolar Vasodilator | 4 |
| Macrolide Antimicrobial | 3 |
| Nitroimidazole Antimicrobial | 2 |
| Cholinergic Muscarinic Antagonist | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Trazodone hydrochloride | 50111-561 | Tablet | Drugs for further processing | June 20, 2025 |
| Trazodone hydrochloride | 50111-560 | Tablet | Drugs for further processing | June 20, 2025 |
| Trazodone hydrochloride | 50111-450 | Tablet | Drugs for further processing | June 20, 2025 |
| Trazodone Hydrochloride | 50111-561 | Tablet | Generic drugs (ANDA) | October 8, 2020 |
| Trazodone Hydrochloride | 50111-560 | Tablet | Generic drugs (ANDA) | October 1, 2020 |
| Trazodone Hydrochloride | 50111-450 | Tablet | Generic drugs (ANDA) | March 11, 2020 |
| Oxybutynin chloride | 50111-456 | Tablet | Drugs for further processing | September 23, 2019 |
| Azithromycin | 50111-788 | Tablet, film coated | Generic drugs (ANDA) | January 6, 2006 |
| Azithromycin | 50111-787 | Tablet, film coated | Generic drugs (ANDA) | January 6, 2006 |
| Azithromycin | 50111-789 | Tablet, film coated | Generic drugs (ANDA) | December 1, 2005 |
| Torsemide | 50111-918 | Tablet | Generic drugs (ANDA) | October 20, 2004 |
| Torsemide | 50111-917 | Tablet | Generic drugs (ANDA) | June 1, 2004 |
| Torsemide | 50111-916 | Tablet | Generic drugs (ANDA) | June 1, 2004 |
| Torsemide | 50111-915 | Tablet | Generic drugs (ANDA) | June 1, 2004 |
| Fluoxetine | 50111-648 | Capsule | Generic drugs (ANDA) | January 29, 2002 |
| Fluoxetine | 50111-647 | Capsule | Generic drugs (ANDA) | January 29, 2002 |
| Oxybutynin Chloride | 50111-456 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
| Hydralazine Hydrochloride | 50111-398 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
| Hydralazine Hydrochloride | 50111-397 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
| Metronidazole | 50111-334 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
| Metronidazole | 50111-333 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
| Hydralazine Hydrochloride | 50111-328 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
| Hydralazine Hydrochloride | 50111-327 | Tablet | Generic drugs (ANDA) | September 30, 1990 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.